KYNB Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -10.25%, SMA50 -17.68%, SMA200 -21.94%). The stock’s 14-day RSI is 37.25 (weak momentum), while the ATR of 0.61 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -46.07% below its high and over 43.71% above its low. Average 10-day trading volume of 8.35 thousand shares is below the 3-month average of 17.69 thousand, indicating normal recent market interest.

Kyntra Bio, Inc. generated EPS of $40.44 over the past year. Five-year average earnings growth is 11.75%. Wall Street analysts project EPS growth of -6.88% annually over the next five years. Kyntra Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended May 11, 2026, missed forecasts by 11.9%. The prior quarter beat by -7.2%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 17, 2025.

Our AI price prediction model suggests that Kyntra Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.89%, with price expected at $6.65 by June 19, 2026, within a range of $6.51 to $6.78 3-Month Outlook: Projected fall of -97.76%, reaching $0.15 by September 03, 2026, with a range of $0.09 to $0.22. 1-Year Outlook: Projected gain of 239.34%, with price at $22.77 by June 04, 2027, within a range of $22.70 to $22.83.

Kyntra Bio, Inc. (NASDAQ:KYNB) shares are flat -2.62% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Kyntra Bio, Inc. trading at a premium to the broader market with a P/E of 0.17. Our AI forecast model points to short-term weakness (-0.89% over two weeks), a medium-term fall (-97.76% over three months), and a longer-term gain (239.34% over one year), with expected trading ranges indicating moderate volatility.

Kyntra Bio, Inc. (NASDAQ:KYNB) closed at $6.71 USD, losing -$0.10 (-1.47%) from the previous close of $6.81. The stock is currently mid-range between its 52-week high and low $4.85 and $12.60. With a market capitalization of about $27.16 million, Kyntra Bio, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.01). Key stats such as the average daily volume over the past year has been around 17.51 thousand shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Kyntra Bio, Inc. operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Thane Wettig, the company employs approximately 225 people and listed since November 14, 2014. Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics.

Kyntra Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $10.61. This means the shares are trading below this model’s fair value.

Kyntra Bio, Inc. trades at a P/E ratio of 0.17, slightly below the S&P 500 average, with a price-to-sales ratio of 3.64 and a price-to-book ratio of -0.62 indicating negative book value, which may reflect financial stress. The P/FCF stands at -1.27, also below market averages.